Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
Volume 1.45M
Average 2.13M
ALDX Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Aldeyra Therapeutics, Inc.NASDAQ: ALDX
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash grows, but more slowly than its trailing trend
Q1 FY2026 net change in cash of $5.04M (cash outflow) rose 20.7% year over year, behind the +134.8% change in trailing-twelve-month net change in cash.
Context
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +20.7% toward the trailing-twelve-month pace of +134.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 15.51M USD
- Year-over-year change
- +117.6%
- 4-year CAGR
- -43.5%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.51M | +117.6% |
| FY2024 | 2024-12-31 | (88.3M) | -5431.1% |
| FY2023 | 2023-12-31 | (1.6M) | +98.1% |
| FY2022 | 2022-12-31 | (85.37M) | -156.2% |
| FY2021 | 2021-12-31 | 151.93M | — |
Net Change in Cash vs competitors
How ALDX compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +134.8% is the 2nd highest of 10, against a peer median of -85.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $103.01M USD | +330.7% | -28.6% | — | |
| LTM Mar 2026 | $102.82M USD | +54.7% | — | — | |
| LTM Mar 2026 | $94.68M USD | -2129.6% | -4.8% | 139.1% | |
| LTM Mar 2026 | $59.21M USD | — | +49.3% | 6425.7% | |
| LTM Mar 2026 | $26.26M USD | -290.0% | -21.3% | 5252.0% | |
| LTM Mar 2026 | $24.68M USD | -85.3% | — | — | |
| LTM Mar 2026 | $14.65M USD | +134.8% | — | — | |
| LTM Mar 2026 | $11.44M USD | +112.1% | — | 5.3% | |
| LTM Dec 2025 | CHF 9.36M CHF | -77.8% | -54.0% | 262.0% | |
GNLXGenelux Corporation | LTM Mar 2026 | $6.93M USD | -157.1% | -7.6% | 86662.5% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $2.31M USD | -137.3% | +285.2% | — |
| Peer median (excluding ALDX) | — | -85.3% | -7.6% | 2757.0% | |
Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Depreciation & Amortization | 264.18K | 258.71K | 262.78K | 249.62K | 251.99K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.11M | 8.29M | 5.75M | 7.97M | 6.09M |
| Change in Working Capital | 7.44M | (3.44M) | 861.18K | 5.91M | (5.18M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 638.06K | (886.08K) | 1.2M | (1.16M) | (21.99K) |
| Other Working Capital | 6.8M | (2.56M) | (343.25K) | 7.07M | (5.16M) |
| Other Non-Cash Items | 409.47K | 283.91K | 339.65K | (1.49M) | (664.43K) |
| Operating Cash Flow | (42.56M) | (56.64M) | (30.33M) | (43.21M) | (33.35M) |
| Capital Expenditures | (7.81K) | (16.32K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 16.32K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (92.94M) | 0 | (96.92M) | (40.26M) |
| Sales of Investments | 0 | 63M | 30M | 52M | 88M |
| Other Investing Activities | 0 | (16.32K) | 0 | 0 | 0 |
| Investing Cash Flow | (7.81K) | (29.95M) | 30M | (44.92M) | 47.74M |
| Debt Repayment | 0 | 0 | (1.04M) | (292.5K) | 0 |
| Common Stock Issued | 189.81M | 1.22M | 305.23K | 121.08K | 1.12M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.68M | 0 | (532.95K) | 0 | (444) |
| Financing Cash Flow | 194.5M | 1.22M | (1.27M) | (171.42K) | 1.12M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 151.93M | (85.37M) | (1.6M) | (88.3M) | 15.51M |
| Free Cash Flow | (42.56M) | (56.65M) | (30.33M) | (43.21M) | (33.35M) |
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.